The U.S. Food and Drug Administration said on Tuesday it had named Scott Steele as acting director of its Center for Biologics Evaluation and Research (CBER), following the exit of top vaccine ...

Dr Peter Marks, who has been director of the FDA's Centre for Biologics Evaluation and Research (CBER) since 2016. The abrupt departure of Peter Marks as the director of the FDA's Centre for ...

Marks, who led the FDA’s vaccine division for more than eight years, resigned on Friday as director of the FDA’s Center for Biologics Evaluation and Research (CBER). Earlier that day ...

Steele also served as a White House adviser on science and technology under George W. Bush, Reuters reported this week. The acting director is slated to lead CBER at a tumultuous moment for the ...

Marks began his role as CBER director in 2016 and has played a ... of “what happens when confidence in well-established science underlying public health and well-being is undermined.” ...

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to ...

given the need for support of science-based novel product development, and their inclusion under CBER authority,” the Leerink analysts said. Choosing the right software translates directly into ...

given the need for support of science-based novel product development, and their inclusion under CBER authority." Meanwhile, Mizuho strategist Jared Holz noted that while the news was expected as ...

An FDA insider for the past five years, Steele has advised on medical policy and served as senior adviser at CBER. He was an adviser on science and technology at the White House during George W.

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.